Lazard Asset Management
RNAC icon

Lazard Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

Lazard Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-371
Closed -$7K – 2331
2023
Q4 		$7K Sell
371
-21
-5% -$627 ﹤0.01% 2109
2023
Q3 		$12K Buy
392
+19
+5% +$635 ﹤0.01% 2137
2023
Q2 		$12K Buy
373
+8
+2% +$286 ﹤0.01% 2173
2023
Q1 		$14K Sell
365
-1,534
-81% -$72.1K ﹤0.01% 2103
2022
Q4 		$63K Buy
1,899
+287
+18% +$12.2K ﹤0.01% 1703
2022
Q3 		$79K Buy
+1,612
New +$88.5K ﹤0.01% 1584
2022
Q1 		– Sell
-619
Closed -$60K – 2495
2021
Q4 		$60K Buy
619
+197
+47% +$21.2K ﹤0.01% 1656
2021
Q3 		$52K Buy
+422
New +$51K ﹤0.01% 1669

Other funds holding RNAC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lazard Asset Management's RNAC Position: Q1 2024 in Review

Lazard Asset Management sold out of Cartesian Therapeutics (RNAC) in Q1 2024, closing a stake of 371 shares — an estimated $7K sold.

Lazard Asset Management first reported a position in RNAC in Q3 2021 and held it in 8 quarters. The position peaked at $79K in Q3 2022. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

  • Lazard Asset Management reported no remaining Cartesian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Lazard Asset Management sold 371 Cartesian Therapeutics shares in Q1 2024, an estimated $7K.
  • Lazard Asset Management first reported a position in Cartesian Therapeutics in Q3 2021 and held it in 8 quarters.
  • Lazard Asset Management's Cartesian Therapeutics position peaked at $79K in Q3 2022.
  • 69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on Lazard Asset Management's 13F filing for Q1 2024, filed 14 May 2024.